Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: a single-institute study of 96 patients. The objective of ...

Timely donor lymphocyte infusion (DLI) following the detection of impending molecular relapse may significantly improve ...

Active influx of imatinib in chronic myeloid leukemia (CML) cells is mediated by the organic cation transporter 1 (OCT-1). Functional activity of OCT-1 (OCT-1 Activity) in mononuclear cells is an ...

Engraftment kinetics in BM or PBSC transplantation (PBSCT) depends on the number and efficiency of stem cells in the graft. Currently, stem cell evaluation is performed by counting CD34+ cells.

October 24, 2011 — In nonstraightforward bone marrow analysis, the presence of 30% or more CD34+ megakaryocytes is a strong indicator of megaloblastic anemia or a myeloid neoplasm, according to a ...

Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461 Thirteen patients (MM, n = 7; NHL, n = 6) ...

CAMBRIDGE, Mass. & HAIFA, Israel--(BUSINESS WIRE)--Minovia Therapeutics, a clinical-stage company focused on the development of cell-based Mitochondrial Augmentation Technology (MAT) to treat ...

Expanding on the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutchinson Cancer Center’s expertise in providing Human CD34+ HSPCs, we have established a high-efficiency and ...

Polycythemia vera is the ultimate phenotypic consequence of the V617F mutation in Janus kinase 2 (encoded by JAK2), but the extent to which this mutation influences the behavior of the involved CD34+ ...

CAMBRIDGE, Mass. & BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s CliniMACS CD34 Reagent ...